Pharmaceuticals
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia
FLORENCE, Italy, Nov. 4, 2021 /PRNewswire/ -- The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
New progress of studies on Lianhua Qingwen's mechanism to fight against SARS-CoV-2
BEIJING, Nov. 4, 2021 /PRNewswire/ -- During the efforts to prevent and control the epidemic, "3 medicines and 3 prescriptions" are selected from traditional Chinese medicine inChina, including the representative medicine "Lianhua Qingwen ", produced by Yiling pharmaceutical, which has been widely...
Envirotainer Opens New station in Guangzhou, China
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that they are opening a new station inGuangzhou, China to provide ground handling of container types RKN e1 and RAP e2. Envirot...
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec S...
Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect
GUANGZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Artequick artemisinin and piperaquine tablets have once again become buzzwords across the globe, as most recently, their effectiveness in treating COVID-19 was hotly debated by live streamers on overseas social media and we media platforms. These dru...
ERT and Bioclinica become Clario, The Leading Technology Solutions Company for Clinical Trial Innovation and Evidence
PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- ERT, the global clinical endpoint technology leader, today announced that following its early Q2 merger with Bioclinica, a technological and scientific leader in medical imaging, the combined company is renamed Clario. Clario is a technology company tha...
Tabernacle Health Group Launches Revolutionary Immunity Booster!
SINGAPORE, Nov. 3, 2021 /PRNewswire/ -- As a result of the pandemic, boosting one's immune system has never been more crucial. Consisting of numerous chemicals, cells, proteins, and tissues that work together, the immune system is responsible for creating, storing, and distributing white blood ce...
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer
Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day...
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...
3M Health Care and Thermo Fisher Scientific Collaborate to Increase Process Efficiency and Scalability in Commercial Therapeutic Manufacturing
- Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers - Solution enables manufacturers to optimize manufacturing capacity, quality, efficiency and scalability ST. PAUL, Minn., Oct. 29, 2021 /PRNewswire/ -- 3M Separation and Purification ...
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...
Interim report for Q3 2021 : Bactiguard Holding AB (publ)
STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...
Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing
* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39